SCHEMBL16239144

SCHEMBL16239144

Cc1cc2sc(NC(=O)C3CCCCN3C(=O)OC(C)(C)C)nc2cc1Cl

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.71
LMNA P02545 3/20 0.52
NPSR1 Q6W5P4 1/20 0.52
CNR2 P34972 5/20 0.49
USP30 Q70CQ3 1/20 0.47
ALDH1A1 P00352 3/20 0.47
NPC1 O15118 3/20 0.47
HPGD P15428 2/20 0.47
ALOX12 P18054 1/20 0.47
HTT P42858 1/20 0.47
NPY4R P50391 2/20 0.47
RAB9A P51151 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
SCN4A P35499 1/20 0.43
CNR1 P21554 1/20 0.42
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13257160 1.00 L3MBTL1 (0.71) L3MBTL1LMNANPSR1CNR2USP30
SCHEMBL16238648 0.87 L3MBTL1 (0.68) L3MBTL1LMNANPSR1CNR2USP30
SCHEMBL13257795 0.87 L3MBTL1 (0.68) L3MBTL1LMNANPSR1CNR2USP30
SCHEMBL16238601 0.87 L3MBTL1 (0.77) L3MBTL1LMNANPSR1CNR2USP30
SCHEMBL13256792 0.87 L3MBTL1 (0.77) L3MBTL1LMNANPSR1CNR2USP30
SCHEMBL13256795 0.87 L3MBTL1 (0.70) L3MBTL1LMNANPSR1CNR2USP30
SCHEMBL16238448 0.87 L3MBTL1 (0.70) L3MBTL1LMNANPSR1CNR2USP30
SCHEMBL13256793 0.83 L3MBTL1 (0.68) L3MBTL1LMNANPSR1CNR2USP30
SCHEMBL13256799 0.83 L3MBTL1 (0.77) L3MBTL1LMNANPSR1USP30ALDH1A1
SCHEMBL16238600 0.83 L3MBTL1 (0.77) L3MBTL1LMNANPSR1USP30ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889670-B2 Heterocyclic compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-18 US disclosed
US-20110312944-A1 Heterocyclic Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312944-A1 Heterocyclic Compounds Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 L3MBTL1 4308/4885LMNA 4475/4885NPSR1 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.